Glaukos (NYSE:GKOS) Upgraded at ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Glaukos (NYSE:GKOS) from a buy rating to a strong-buy rating in a report issued on Friday morning, ValuEngine reports.

GKOS has been the topic of several other research reports. Zacks Investment Research upgraded Glaukos from a sell rating to a hold rating and set a $76.00 price objective on the stock in a report on Thursday, September 12th. JPMorgan Chase & Co. set a $90.00 price objective on Glaukos and gave the stock a buy rating in a report on Thursday, October 10th. BTIG Research reiterated a hold rating on shares of Glaukos in a report on Wednesday, October 30th. Finally, Bank of America downgraded Glaukos from a buy rating to an underperform rating and set a $67.00 price objective on the stock. in a report on Monday, September 30th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Glaukos presently has a consensus rating of Buy and an average target price of $74.75.

NYSE GKOS opened at $64.13 on Friday. The stock’s 50-day simple moving average is $63.28 and its two-hundred day simple moving average is $67.98. Glaukos has a twelve month low of $50.60 and a twelve month high of $84.65. The company has a quick ratio of 5.94, a current ratio of 6.32 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of -173.32 and a beta of 1.68.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.07. Glaukos had a negative return on equity of 4.01% and a negative net margin of 8.60%. The business had revenue of $58.51 million for the quarter, compared to the consensus estimate of $56.96 million. During the same quarter last year, the business posted ($0.17) earnings per share. The company’s revenue for the quarter was up 33.2% on a year-over-year basis. On average, equities analysts expect that Glaukos will post -0.35 earnings per share for the current fiscal year.

In other news, CFO Joseph E. Gilliam sold 2,500 shares of Glaukos stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $73.25, for a total value of $183,125.00. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders sold 10,881 shares of company stock worth $716,702. Company insiders own 8.70% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Harvest Fund Management Co. Ltd purchased a new position in Glaukos during the 2nd quarter valued at about $39,000. Marshall Wace North America L.P. purchased a new position in Glaukos during the 1st quarter valued at about $55,000. NEXT Financial Group Inc increased its holdings in Glaukos by 73.7% during the 2nd quarter. NEXT Financial Group Inc now owns 1,129 shares of the medical instruments supplier’s stock valued at $85,000 after purchasing an additional 479 shares during the period. First Quadrant L P CA purchased a new position in Glaukos during the 2nd quarter valued at about $86,000. Finally, Meeder Asset Management Inc. increased its holdings in Glaukos by 144.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 1,509 shares of the medical instruments supplier’s stock valued at $114,000 after purchasing an additional 891 shares during the period.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.

Read More: How to calculate the annual rate of depreciation

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.